Identifying Features of Tamoxifen Resistant Breast Tumors
Author Information
Author(s): Huang Lei, Zhao Shuangping, Frasor Jonna M., Dai Yang
Primary Institution: University of Illinois at Chicago
Hypothesis
Can an integrated bioinformatics approach uncover mechanisms contributing to tamoxifen resistance in breast tumors?
Conclusion
The study found that tamoxifen resistant tumors exhibit elevated cyclin E2 expression and E2F activity, suggesting potential therapeutic strategies.
Supporting Evidence
- Tamoxifen resistant tumors showed enriched expression of genes related to cell cycle and proliferation.
- Connectivity Map analysis identified small molecules that could reverse gene expression patterns in tamoxifen resistant tumors.
- Validation studies confirmed that phenothiazines can down-regulate cyclin E2 and inhibit proliferation in resistant breast cancer cells.
Takeaway
Some breast cancer tumors don't respond to tamoxifen treatment, and this study looked at their genes to find out why and how to help treat them better.
Methodology
The study analyzed three gene expression datasets from breast tumors to identify differentially expressed genes and their functional pathways.
Limitations
The study primarily focused on gene expression without exploring all potential biological mechanisms of resistance.
Participant Demographics
ER positive breast cancer patients treated with tamoxifen.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website